REnal TrAIning & reteNtion (RETAIN) Program
肾脏训练
基本信息
- 批准号:8855541
- 负责人:
- 金额:$ 30.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This is a new application for a T32 in response to NIDDK's request to combine Nephrology's T32, which was in its 27th year, director Mark S. Segal MD/PhD Chief, Division of Nephrology, and Physiology's T32, which was in its 5th year, director Charles Wood Ph.D. is the Chair of the Department of Physiology and Functional Genomics. The rationale for the new program is that there remains a critical need for researchers to investigate the etiologies, pathogenesis, management, and consequences of kidney diseases. This T32 is unique since it combines Physiology's strength in pre-natal programing with the Nephrology's strength in translational research. The objective of this training grant is to provide superb training in basic, translational, or clinical research in the feld of kidney diseases. Training will be provided to both predoctoral (4 PhD, PharmD, or MD- PhD students) and postdoctoral (2 MDs, PhDs, or PharmDs) trainees, for 2 to 3 years. The faculty consists of clinician-scientists and basic scientists whose research is concentrated in areas important for understanding the basis of chronic kidney disease and its sequelae. The predoctoral trainees will be recruited and trained through the College of Medicine's Interdisciplinary Program in Biomedical Sciences (IDP) or the College of Pharmacy. Postdoctoral trainees will be recruited through T32 program faculty and national advertising. All trainees will have a primary mentor, a renal mentor (if the primary mentor is not in the Division of Nephrology), and a basic science or epidemiologic mentor. For those who enter clinical research an MPH in the School of Public Health can be obtained. This T32 program was developed with specific mechanisms to enhance recruitment of qualified personal into translational research and to help ensure their future success. Relevance. A major consequence of the epidemic of obesity, metabolic syndrome, and diabetes has been a dramatic increase in patients suffering from kidney disease. Currently there are nearly 30 million individuals with variable degrees of kidney dysfunction, with nearly 800,000 with either end stage or near end stage kidney disease. Add to this the nearly 5 million individuals discharged from the hospital after suffering acute kidney injury and the recent realization that these individuals are increased risk for morbidity and mortality leads to a tremendous need for kidney investigation. This training grant provides a focused program for training promising candidates in basic, translational, and clinical research which should help them prepare for an academic career in nephrology.
描述(由应用程序提供):这是T32的新应用程序,以响应NIDDK的请求结合肾脏病的T32的要求,该公司已于27岁,导演Mark S. Segal MD/PhD肾脏病和Physiology的T32负责人Mark S. Segal MD/PhD负责人T32,该公司的T32是第5年的Charles Wood Ph.D. Charles WoodPh.D。是生理和功能基因组学系主任。新计划的理由是,研究人员仍需要研究肾脏疾病的病因,发病机理,管理和后果。该T32是独一无二的,因为它将生理学在产前编程中的力量与肾脏学在翻译研究中的优势相结合。这项培训补助金的目的是在肾脏疾病饲料中提供基本,翻译或临床研究的精湛培训。将向培训提供2至3年的培训(4博士学位,PharmD或MD-PHD学生)和博士后(2 MDS,PHD或PHARMDS)受训者2至3年。该教师由临床科学家和基础科学家组成,他们的研究集中在了解慢性肾脏疾病及其后遗症基础的重要领域。托管前学员将通过医学院的生物医学科学跨学科计划(IDP)或药学院招募和培训。博士后学员将通过T32计划教师和国家广告招募。所有学员将具有主要的心理,肾脏心理(如果主要的精神不在肾脏科中),以及基础科学或流行病学的心理。对于那些进入临床研究的人,可以在公共卫生学院获得MPH。该T32计划采用特定机制开发,以增强合格的个人招募到转化研究,并帮助确保其未来的成功。关联。肥胖,代谢综合征和糖尿病流行的主要结果是患有肾脏疾病的患者的急剧增加。目前,有近3000万个肾功能障碍程度可变的人,近80万人患有末端阶段或近端肾脏疾病。此外,在急性肾脏损伤后,将近500万人从医院出院,并且最近意识到这些人患发病和死亡率的风险增加导致对肾脏调查的巨大需求。该培训补助金为基础,翻译和临床研究中的培训承诺候选者提供了重点计划,该计划应有助于他们为肾脏科学的学术事业做准备。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
MARK S. SEGAL的其他基金
Hydroxychloroquine for the Management of CVD in CKD
羟氯喹用于治疗 CKD 中的 CVD
- 批准号:1057865110578651
- 财政年份:2018
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Hydroxychloroquine for the Management of CVD in CKD
羟氯喹用于治疗 CKD 中的 CVD
- 批准号:1029515710295157
- 财政年份:2018
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Hydroxychloroquine for the Management of CVD in CKD
羟氯喹用于治疗 CKD 中的 CVD
- 批准号:95615519561551
- 财政年份:2018
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Hydroxychloroquine for the Management of CVD in CKD
羟氯喹用于治疗 CKD 中的 CVD
- 批准号:1003879510038795
- 财政年份:2018
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI & PICS
肾脏对脓毒症的反应影响血管生成平衡和 CCI 的可能性
- 批准号:87407218740721
- 财政年份:2014
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Uric Acid and Hypertension in African-Americans
非裔美国人的尿酸和高血压
- 批准号:74136577413657
- 财政年份:2005
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Ionic Charge and pH Regulation of Apoptotic Signaling
细胞凋亡信号传导的离子电荷和 pH 调节
- 批准号:65179476517947
- 财政年份:2001
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Ionic Charge and pH Regulation of Apoptotic Signaling
细胞凋亡信号传导的离子电荷和 pH 调节
- 批准号:63603236360323
- 财政年份:2001
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS
慢病毒基因转移至胰腺β细胞
- 批准号:61760676176067
- 财政年份:1998
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS
慢病毒基因转移至胰腺β细胞
- 批准号:65166976516697
- 财政年份:1998
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
相似国自然基金
CD40hiCD138hiPIR-Ahi巨噬细胞训练免疫的形成及其促进慢性排斥反应的机制研究
- 批准号:82371794
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
面向底层视觉任务的通用自监督预训练基础模型研究
- 批准号:62371164
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
认知原理启发的训练仿真系统战场空间表示方法研究
- 批准号:62306329
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
支持深度伪造检测的精细化高效训练集生成方法研究
- 批准号:62372423
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
面向大规模图预训练模型的知识迁移关键问题研究
- 批准号:62376129
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
DULCE (Diabetes InqUiry Through a Learning Collaborative Experience)
DULCE(通过学习协作体验进行糖尿病查询)
- 批准号:1055811910558119
- 财政年份:2023
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
Defining the neural basis for persistent obesity
定义持续性肥胖的神经基础
- 批准号:1073512810735128
- 财政年份:2023
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
TRIO Professional Development Core
TRIO 专业发展核心
- 批准号:1072547210725472
- 财政年份:2023
- 资助金额:$ 30.87万$ 30.87万
- 项目类别:
School-Partnered Collaborative Care (SPACE) for Pediatric Type 1 Diabetes
针对儿童 1 型糖尿病的学校合作协作护理 (SPACE)
- 批准号:1064061410640614
- 财政年份:2023
- 资助金额:$ 30.87万$ 30.87万
- 项目类别: